Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. (Q40142974)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Peter Richmond

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Leon G Heron

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ming Qiao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Joanne Marjason

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Laurent Chambonneau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alain Bouckenooghe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mark Boaz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Diane van der Vliet

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Derek Wallace

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Yanee Hutagalung

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Michael D Nissen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

13 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

5127-5134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26279339%20AND%20SRC:MED&resulttype=core&format=json

Global traffic and disease vector dispersal

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

The global distribution and burden of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Dengue in the Americas: challenges for prevention and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Dengue: an escalating public health problem in Latin America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Dengue and dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Spectrum of disease and relation to place of exposure among ill returned travelers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Seroepidemiology of dengue in travellers: a paired sera analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Development of Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008

Efficacy of a tetravalent dengue vaccine in children in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.008